Microsure Closes €38M Series B2 Financing to Advance MUSA-3 Microsurgical Robot

Eindhoven-based Microsure has closed €38 million Series B2 financing to complete the development of its latest microsurgical robot, MUSA-3, for clinical studies in preparation for US FDA clearance and CE mark.

MUSA-3 represents a monumental leap in microsurgical technology, providing surgeons with unprecedented precision, stability and control beyond human capabilities, taking patient care to new heights in the future of microsurgery.

MUSA-3 offers enhanced dexterity and a large working area, tremor reduction for improved precision and seamless integration with surgeons’ existing preferred micro-instruments from several leading brands. Combining surgeon comfort with improved ergonomics, MUSA-3 allows surgeons to work from a surgeon’s console with digital exoscopes or hybrid surgical microscopes, and its adaptability allows it for a wide range of surgical procedures.

A number of new investors participated in this financing, including the European Innovation Council Fund (EICF), kineo finance, Invest-NL, and several prominent private investor groups.

Microsure also acknowledges the unwavering support of key existing shareholders, including deep-tech venture capital firm Innovation Industries, BOM Ventures, private investors Ten Cate Investerings Maatschappij (TCIM), Venturing Tech, Eindhoven University of Technology (TU/e) and Microsure Founders.

To view the source version, please click HERE.